Raffles Medical Likely a Defensive Option Amid Volatility -- Market Talk

Dow Jones

Apr 08, 2025

0339 GMT - Raffles Medical Group is a likely defensive option in a volatile market, RHB Research's Shekhar Jaiswal says in a research report. Patient load for its healthcare business has normalized and this segment is now devoid of pandemic-related revenue, implying annual healthcare revenue may now exceed prepandemic levels, the analyst says. The hospital business should also enjoy higher revenue as its China-based hospitals, which had been affected by pandemic restrictions,start to scale up their operations, the analyst adds. RHB upgrades the stock to buy from neutral and raises the target price to S$1.08 from S$0.95 to factor in the defensive nature of Raffles Medical's earnings in the current uncertain macroeconomic environment. Shares are 2.7% higher at S$0.945. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

April 07, 2025 23:39 ET (03:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525870887"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525870887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525870887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 11:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525870887","market":"fut","top_or_hot":-1,"title":"Raffles Medical Likely a Defensive Option Amid Volatility -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0339 GMT - Raffles Medical Group is a likely defensive option in a volatile market, RHB Research's Shekhar Jaiswal says in a research report. Patient load for its healthcare business has normalized and this segment is now devoid of pandemic-related revenue, implying annual healthcare revenue may now exceed prepandemic levels, the analyst says. The hospital business should also enjoy higher revenue as its China-based hospitals, which had been affected by pandemic restrictions,start to scale up their operations, the analyst adds. RHB upgrades the stock to buy from neutral and raises the target price to S$1.08 from S$0.95 to factor in the defensive nature of Raffles Medical's earnings in the current uncertain macroeconomic environment. Shares are 2.7% higher at S$0.945. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 23:39 ET (03:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical Likely a Defensive Option Amid Volatility -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical Likely a Defensive Option Amid Volatility -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-08 11:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0339 GMT - Raffles Medical Group is a likely defensive option in a volatile market, RHB Research's Shekhar Jaiswal says in a research report. Patient load for its healthcare business has normalized and this segment is now devoid of pandemic-related revenue, implying annual healthcare revenue may now exceed prepandemic levels, the analyst says. The hospital business should also enjoy higher revenue as its China-based hospitals, which had been affected by pandemic restrictions,start to scale up their operations, the analyst adds. RHB upgrades the stock to buy from neutral and raises the target price to S$1.08 from S$0.95 to factor in the defensive nature of Raffles Medical's earnings in the current uncertain macroeconomic environment. Shares are 2.7% higher at S$0.945. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 23:39 ET (03:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSL.SI","symbol_name":"莱佛士医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525870887","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525870887","pubTimestamp":1744083540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0339 GMT - Raffles Medical Group is a likely defensive option in a volatile market, RHB Research's Shekhar Jaiswal says in a research report. Patient load for its healthcare business has normalized and this segment is now devoid of pandemic-related revenue, implying annual healthcare revenue may now exceed prepandemic levels, the analyst says. The hospital business should also enjoy higher revenue as its China-based hospitals, which had been affected by pandemic restrictions,start to scale up their operations, the analyst adds. RHB upgrades the stock to buy from neutral and raises the target price to S$1.08 from S$0.95 to factor in the defensive nature of Raffles Medical's earnings in the current uncertain macroeconomic environment. Shares are 2.7% higher at S$0.945. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSL.SI":"莱佛士医疗","BK6511":"医疗保健服务概念","BK6092":"保健护理机构"},"translate_title":"莱佛士医疗可能是波动中的防御性选择——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1},"content_text":"0339 GMT - Raffles Medical Group is a likely defensive option in a volatile market, RHB Research's Shekhar Jaiswal says in a research report. Patient load for its healthcare business has normalized and this segment is now devoid of pandemic-related revenue, implying annual healthcare revenue may now exceed prepandemic levels, the analyst says. The hospital business should also enjoy higher revenue as its China-based hospitals, which had been affected by pandemic restrictions,start to scale up their operations, the analyst adds. RHB upgrades the stock to buy from neutral and raises the target price to S$1.08 from S$0.95 to factor in the defensive nature of Raffles Medical's earnings in the current uncertain macroeconomic environment. Shares are 2.7% higher at S$0.945. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 23:39 ET (03:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}